ClariVest Asset Management LLC Sells 12,653 Shares of Applied Genetic Technologies Co. (AGTC)

ClariVest Asset Management LLC reduced its holdings in shares of Applied Genetic Technologies Co. (NASDAQ:AGTC) by 10.3% during the 1st quarter, according to the company in its most recent 13F filing with the SEC. The institutional investor owned 109,700 shares of the biotechnology company’s stock after selling 12,653 shares during the period. ClariVest Asset Management LLC owned about 0.61% of Applied Genetic Technologies worth $422,000 at the end of the most recent reporting period.

Several other institutional investors have also modified their holdings of the company. Two Sigma Investments LP boosted its position in shares of Applied Genetic Technologies by 29.9% during the 4th quarter. Two Sigma Investments LP now owns 60,892 shares of the biotechnology company’s stock valued at $219,000 after acquiring an additional 14,011 shares in the last quarter. Spark Investment Management LLC boosted its position in shares of Applied Genetic Technologies by 122.1% during the 4th quarter. Spark Investment Management LLC now owns 107,700 shares of the biotechnology company’s stock valued at $387,000 after acquiring an additional 59,200 shares in the last quarter. Renaissance Technologies LLC boosted its position in shares of Applied Genetic Technologies by 32.5% during the 4th quarter. Renaissance Technologies LLC now owns 444,428 shares of the biotechnology company’s stock valued at $1,600,000 after acquiring an additional 109,128 shares in the last quarter. Municipal Employees Retirement System of Michigan boosted its position in shares of Applied Genetic Technologies by 66.7% during the 4th quarter. Municipal Employees Retirement System of Michigan now owns 311,820 shares of the biotechnology company’s stock valued at $1,123,000 after acquiring an additional 124,810 shares in the last quarter. Finally, Dimensional Fund Advisors LP boosted its position in shares of Applied Genetic Technologies by 48.1% during the 3rd quarter. Dimensional Fund Advisors LP now owns 394,490 shares of the biotechnology company’s stock valued at $1,558,000 after acquiring an additional 128,049 shares in the last quarter. Institutional investors and hedge funds own 44.85% of the company’s stock.

AGTC has been the subject of several analyst reports. ValuEngine downgraded shares of Applied Genetic Technologies from a “sell” rating to a “strong sell” rating in a report on Thursday, March 1st. Zacks Investment Research raised shares of Applied Genetic Technologies from a “sell” rating to a “hold” rating in a report on Friday, March 30th. Wedbush reissued an “outperform” rating on shares of Applied Genetic Technologies in a report on Friday, February 9th. Finally, HC Wainwright set a $8.00 price target on shares of Applied Genetic Technologies and gave the company a “buy” rating in a report on Friday, February 9th. One analyst has rated the stock with a sell rating, two have assigned a hold rating and four have assigned a buy rating to the company. Applied Genetic Technologies has a consensus rating of “Hold” and an average price target of $9.00.

Shares of Applied Genetic Technologies opened at $5.65 on Tuesday, Marketbeat.com reports. Applied Genetic Technologies Co. has a 12-month low of $3.25 and a 12-month high of $6.05. The stock has a market cap of $102.32 million, a P/E ratio of 282.50 and a beta of 2.07.

Applied Genetic Technologies (NASDAQ:AGTC) last announced its quarterly earnings results on Tuesday, May 8th. The biotechnology company reported ($0.45) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.41) by ($0.04). Applied Genetic Technologies had a negative net margin of 65.96% and a negative return on equity of 16.00%. The firm had revenue of $3.60 million for the quarter, compared to the consensus estimate of $6.41 million. equities analysts predict that Applied Genetic Technologies Co. will post -1.38 earnings per share for the current fiscal year.

Applied Genetic Technologies Company Profile

Applied Genetic Technologies Corporation, a clinical-stage biotechnology company, develops transformational genetic therapies for patients suffering from rare and debilitating diseases. The company's lead products consist of four ophthalmology development programs across three targets, including X-linked retinoschisis that is in Phase I/II clinical trials; X-linked retinitis pigmentosa, which is in Phase I/II clinical trials; and achromatopsia that is in Phase I/II clinical trials for the treatment of inherited retinal diseases, as well as a preclinical program in adrenoleukodystrophy, which is a disease of the central nervous system and otology.

Want to see what other hedge funds are holding AGTC? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Applied Genetic Technologies Co. (NASDAQ:AGTC).

Institutional Ownership by Quarter for Applied Genetic Technologies (NASDAQ:AGTC)

Receive News & Ratings for Applied Genetic Technologies Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Applied Genetic Technologies and related companies with MarketBeat.com's FREE daily email newsletter.




Leave a Reply